Cadrenal Therapeutics has announced the signing of a collaboration agreement with Abbott to support Cadrenal’s pivotal TECH-LVAD trial.
Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on developing specialised therapeutics for rare cardiovascular conditions.
The company is developing its late-stage asset, tecarfarin, an oral vitamin K antagonist (VKA) designed to be a better and safer anticoagulant than warfarin, for individuals with implanted cardiac devices.
Under the terms of the agreement, Abbott will support Cadrenal on the planning and execution of the TECH-LVAD trial to evaluate the efficacy and safety of tecarfarin in patients with left ventricular assist devices (LVADs). Abbott will share insights from recent HeartMate 3 trials and will support Cadrenal with trial design, site identification, trial awareness, and LVAD expertise.
“We are pleased to have the support of Abbott, a global healthcare leader, which further validates the advancement into late-stage clinical development of tecarfarin. This partnership strengthens our access to key clinical trial sites and enhances patient enrolment efforts,” said Quang X Pham, chief executive officer, Cadrenal Therapeutics. “Together, we have a unique opportunity to evaluate tecarfarin in combination with the HeartMate 3 LVAD, advancing our commitment to bringing forward the first innovation in vitamin K-targeted anticoagulation in over 70 years.”
Abbott’s HeartMate 3 LVAD is a mechanical circulatory support device designed for patients with advanced heart failure.
